Danaher Corporation (DHR)
| Market Cap | 138.86B |
| Revenue (ttm) | 24.78B |
| Net Income (ttm) | 3.69B |
| Shares Out | 707.77M |
| EPS (ttm) | 5.18 |
| PE Ratio | 38.03 |
| Forward PE | 22.89 |
| Dividend | $1.60 (0.82%) |
| Ex-Dividend Date | Jun 26, 2026 |
| Volume | 6,090,465 |
| Open | 192.83 |
| Previous Close | 192.81 |
| Day's Range | 192.29 - 196.19 |
| 52-Week Range | 160.93 - 242.80 |
| Beta | 0.83 |
| Analysts | Strong Buy |
| Price Target | 242.35 (+23.53%) |
| Earnings Date | Jul 21, 2026 |
About DHR
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufact... [Read more]
Financial Performance
In 2025, Danaher's revenue was $24.57 billion, an increase of 2.90% compared to the previous year's $23.88 billion. Earnings were $3.61 billion, a decrease of -7.31%.
Financial StatementsAnalyst Forecast
According to 26 analysts, the average rating for DHR stock is "Strong Buy." The 12-month stock price target is $242.35, which is an increase of 23.53% from the latest price.
News
The Big 3: JPM, DHR, MRK
Dan Deming talks joins today's Big 3 and highlights JPMorgan Chase (JPM) as shares touch new record highs. He sees Danaher (DHR) as a candidate for a continuing breakout, noting a similar pattern in M...
Danaher Schedules Second Quarter 2026 Earnings Conference Call
WASHINGTON, June 22, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the second quarter 2026 on Tuesday, July 21, 2026 be...
Danaher’s Masimo receives FDA 510k clearance for OIRD detection on Radius VSM
Masimo, a Danaher (DHR) company, announced FDA 510(k) clearance for an opioid-induced respiratory depression, OIRD, detection capability integrated into the Radius VSM wearable continuous patient moni...
Danaher initiated with a Neutral at Piper Sandler
Piper Sandler initiated coverage of Danaher (DHR) with a Neutral rating and $200 price target The firm launched coverage of the life science tools sector with a “feet in the…
Danaher completes acquisition of Masimo
Danaher (DHR), a global science and technology innovator, announced today that it has completed the acquisition of Masimo (MASI). Masimo’s trusted brand, advanced sensor technology and AI-enabled pati...
Danaher Completes Acquisition of Masimo Corporation
WASHINGTON, June 10, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR), a global science and technology innovator, announced today that it has completed the acquisition of Masimo Corporation, a lea...
Sirius XM Holdings Set to Join S&P MidCap 400
NEW YORK, June 8, 2026 /PRNewswire/ -- Sirius XM Holdings Inc. (NASD: SIRI) will replace Masimo Corp. (NASD: MASI) in the S&P MidCap 400 effective prior to the opening of trading on Thursday, June 11....
Sirius XM to replace Masimo in S&P 400 at open on 6/11
Sirius XM Holdings (SIRI) will replace Masimo (MASI) in the S&P MidCap 400 effective prior to the opening of trading on Thursday, June 11. Danaher (DHR) is acquiring Masimo in…
Danaher price target lowered to $230 from $270 at HSBC
HSBC lowered the firm’s price target on Danaher (DHR) to $230 from $270 and keeps a Buy rating on the shares. The firm says market expectations on life science tools…
Danaher initiated with a Buy at DZ Bank
DZ Bank initiated coverage of Danaher (DHR) with a Buy rating and $210 price target
Danaher assumed with Peer Perform at Wolfe Research
As previously reported, Wolfe Research analyst Mike Polark downgraded Danaher (DHR) to Peer Perform from Outperform with no price target after assuming coverage of the name. Growth forward and backwar...
Danaher assumed with Peer Perform from Outperform at Wolfe Research
Wolfe Research analyst Mike Polark downgraded Danaher (DHR) to Peer Perform from Outperform after assuming coverage of the name.
SCIEX Advances the ZenoTOF Line With Platform-Wide Expansions in Software, Integrations, and Key Collaborations
MARLBOROUGH, Mass.--(BUSINESS WIRE)-- #massspec--SCIEX advances the ZenoTOF line with platform-wide expansions in software, integrations, and key collaborations.
SCIEX Launches the novus V55 System With SCIEX OS 5.0 Software and AI Enablement Tools
MARLBOROUGH, Mass.--(BUSINESS WIRE)-- #V55--SCIEX launches the novus V55 system with SCIEX OS 5.0 software and AI enablement tools.
Integrated DNA Technologies enters collaboration with Illumina
Integrated DNA Technologies (DHR) announced a strategic collaboration with Illumina (ILMN) to enable a DRAGEN secondary analysis pipeline for IDT xGen FFPE and cfDNA next generation sequencing library...
Danaher resumed with a Buy at Citi
Citi resumed coverage of Danaher (DHR) with a Buy rating and $230 price target following a suspension of the rating. Danaher reiterated its fiscal 2026 core growth guidance when reporting…
Danaher resumed with an Outperform at RBC Capital
RBC Capital resumed coverage of Danaher (DHR) with an Outperform rating and $200 price target The firm sees the company’s growth recovering with the bioprocess market improving. A sustained bioprocess...
Danaher Transcript: Bank of America Global Healthcare Conference 2026
Solid first quarter with 300 basis points of core growth, strong bioprocessing and diagnostics momentum, and robust performance in life sciences. Guidance for 3%-6% organic growth is maintained, with headwinds expected to fade and capital deployment focused on M&A and strategic investments.
Danaher to Present at Bank of America Securities Healthcare Conference
WASHINGTON, May 6, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Rainer M. Blair, will be presenting at the Bank of America Securities Heal...
Danaher Announces Quarterly Dividend
WASHINGTON, May 5, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.40 per share of its common stoc...
Danaher Transcript: AGM 2026
The meeting covered director elections, auditor reappointment, executive compensation, and incentive plan approval, all passing with strong majorities. Financial results showed $24.6B in revenue, high margins, and strong recurring revenue, with a focus on life sciences and diagnostics.
Masimo shareholders approve acquisition by Danaher
Masimo (MASI) announced that its stockholders voted in favor of the proposal to adopt the previously announced Agreement and Plan of Merger, dated February 16, 2026, by and among Masimo,…
Masimo Shareholders Approve Acquisition by Danaher
IRVINE, Calif.--(BUSINESS WIRE)--Masimo Corporation (Nasdaq: MASI) (“Masimo”), a leading global innovator in patient monitoring, today announced that its stockholders voted in favor of the proposal to...